Related references
Note: Only part of the references are listed.Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
Paul V. Viscuse et al.
FRONTIERS IN ONCOLOGY (2021)
Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin
Rui Sasaki et al.
JOURNAL OF DERMATOLOGY (2020)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis
Seth R. Flaxman et al.
LANCET GLOBAL HEALTH (2017)
Etiopathogenesis of cataract: An appraisal
Varun B. Gupta et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2014)
The cell adhesion gene PVRL3 is associated with congenital ocular defects
Salil A. Lachke et al.
HUMAN GENETICS (2012)
Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens: A model for cataract formation
RU de Iongh et al.
CELLS TISSUES ORGANS (2005)
Share Paper
